Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

60275 1492790397HCLSReviewGreeceApril2017.pdf
Energy Boardroom

CA panel shivs Gilead's Sovaldi on price, suggests focusing it on sickest hep C patients

12.03.2014 / Fierce Pharma

Payers are growing increasingly balky at the price Gilead Sciences slapped on its breakthrough hepatitis C pill Sovaldi. An expert panel in California that assesses new treatments voted Sovaldi a "low value" treatment–not because it doesn't work well enough, but because of its $1,000-a-pill price tag.

Cover_HCLS_GREECE LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: